Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

Completed · Phase 2

Conditions studied: Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer

In brief

A Pilot Phase II Study The primary objective for this study is: * To explore the usefulness of \[F-18\]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full course of treatment is completed The secondary objectives for this study are: * To continue safety evaluation by collection of safety data from all patients * To gain experience with \[F-18\]RGD-K5 PET/CT in order to improve the study design and conduct of future studies Design: An open label, non-randomized, uncontrolled, single group assignment, pilot efficacy study Duration: Screening visit (3-4 hrs), pre-treatment imaging visit of \[F-18\]RGD-K5 PET/CT (\~ 3-4 hrs) and the standard \[F-18\]FDG PET/CT (\~ 3-4 hrs) or diagnostic CT, followed by two \[F-18\]RGD-K5 PET/CT scans, one after the second but before the third Avastin® treatment, and one after the fourth but before the fifth Avastin® treatment, and a follow up standard \[F-18\]FDG PET (\~ 3-4 hrs) or diagnostic CT. Procedures: Informed consent, collection of demographic information, medical history, blood labs, physical examination, vital signs, ECGs, three sets of \[F-18\]RGD-K5 dosing and imaging scans including pretreatment, early mid-treatment, and later mid-treatment, concomitant medication collection, adverse event monitoring, and assessment of tumor response to treatment Patients: Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer who will receive chemotherapy plus Avastin®. This allows for approximately 30 evaluable patients to complete this study at approximately four to eight sites internationally

Key facts

Study ID: NCT00988936
Run by: Siemens Molecular Imaging
People needed: 35
Starts: 2009-09-01
Expected to finish: 2012-05-01
Last updated by the study team: 2012-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient is >18 years and male or female of any race / ethnicity
Patient or patient's legally acceptable representative provides written informed consent and willing to comply with protocol requirements
Patient must be scheduled to receive chemotherapy treatment(s) plus Avastin® for their cancer care; treatment management will be made by the treating medical oncologists (According to the package insert for Avastin®, it is administered as an IV infusion every 3 weeks for nonsquamous non-small cell lung cancer, and every 2 weeks for metastatic breast cancer, colon or rectum cancer)
Patient will be scheduled to have a clinical [F-18]FDG-PET/CT or diagnostic CT pre-treatment after the fourth but before the fifth Avastin® treatment

You may not qualify if…

Patient is not capable of complying with study procedures
Female patient is pregnant or nursing; exclude the possibility of pregnancy by one of the following:
Confirming in medical history that the patient is postmenopausal for a minimum of one year, or surgically sterile
Confirming the patient is using one of the following methods of birth control for a minimum of one month prior to entry into this study: IUD, oral contraceptives, Depo-Provera, or Norplant
Confirming a negative urine dipstick test taken the morning of receiving the [F-18]RGD-K5
Patient has a severe hepatic or renal disease as defined by previous medical history or abnormal renal and hepatic functions determined by lab results not within the following ranges, or in the opinion of the Investigator, the values are not acceptable for the patient to be included:
AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limits of normal
Serum creatinine ≤ 2x institutional upper limits of normal
BUN within 2x institutional upper limits of normal
Patient has known hyper or hypo-coagulation syndromes. (e.g. Protein C, S deficiency, Hemophilia A/B/C, Factor-V Leiden, etc) or lab results are not within the following ranges, or in the opinion of the Investigator, the values are not acceptable for the patient to be included: Platelet counts of < 75 x 103/μL
Patient has known sensitivity to any components of Avastin® such as recombinant human or humanized antibodies
Patient has been involved in an investigative, radioactive research procedure within 7 days and during the study participation period
Patient will participate in experimental therapy procedures while participating in this clinical trial
Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality to achieve study objectives, or complete study and/or post-dose follow-up examinations

Where it is running

University of California, Irvine — Irvine, California, United States
Cedars-Sinai Medical Center — Los Angeles, California, United States
UMDNJ — Newark, New Jersey, United States
Beth Israel Medical Center — New York, New York, United States
Mount Sinai School of Medicine — New York, New York, United States
Hospital of University of Pennsylvania — Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
Eastern Regional Medical Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.